CA209-762: Fine needle aspiration (EUS/EBUS) versus histology for PD-L1 staining in lung cancer
- Conditions
- on-small cell lungcancer (NSCLC)Niet-kleincellig longkanker
- Registration Number
- NL-OMON21496
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1. Histologically confirmed stage IIIB and stage IV NSCLC
2. Smokers or ex-smokers with at least 15 Pack Years.
Exclusion Criteria
1. Previous treatment with PD-1 or PD-L1 inhibitor.
2. Pregnant or lactating women.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Explore the agreement between cytology blocks and histology tissue, both stained for the presence of PD-L1.
- Secondary Outcome Measures
Name Time Method Explore for which patients with PD-L1 expression, the treatment with PD-1/PD-L1 inhibitors will lead to a durable response. A durable response is defined by having clinical benefit from a PD-(L)1 inhibitor for at least one year of treatment. For that, the included patients being treated with PD-(L)1 inhibitors, will be divided into two groups (those with durable response versus those without durable response).